Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M.

Breast Cancer Res Treat. 2011 Jan;125(1):35-42. doi: 10.1007/s10549-010-0819-x. Epub 2010 Mar 11.

PMID:
20221692
2.

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M.

Int J Cancer. 2011 Apr 15;128(8):1813-21. doi: 10.1002/ijc.25512.

3.

Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.

Liu W, Ip MM, Podgorsak MB, Das GM.

Breast Cancer Res Treat. 2009 May;115(1):43-50. doi: 10.1007/s10549-008-0044-z. Epub 2008 May 15.

4.

p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.

Anaganti S, Fernández-Cuesta L, Langerød A, Hainaut P, Olivier M.

Cancer Lett. 2011 Jan 28;300(2):215-24. doi: 10.1016/j.canlet.2010.10.008. Epub 2010 Nov 10.

PMID:
21071137
5.

Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.

Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA, Das GM.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15081-6. doi: 10.1073/pnas.1009575107. Epub 2010 Aug 9.

6.

Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.

Lu W, Katzenellenbogen BS.

Horm Cancer. 2017 Aug;8(4):230-242. doi: 10.1007/s12672-017-0298-1. Epub 2017 Jun 2.

PMID:
28577282
7.

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.

Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP.

Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.

8.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
9.

p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.

Berger CE, Qian Y, Liu G, Chen H, Chen X.

J Biol Chem. 2012 Aug 31;287(36):30117-27. doi: 10.1074/jbc.M112.367326. Epub 2012 Jul 11.

10.

A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA.

Breast Cancer Res Treat. 2010 Jul;122(2):381-93. doi: 10.1007/s10549-009-0580-1. Epub 2009 Oct 20.

11.

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S.

Biochim Biophys Acta. 2013 Mar;1830(3):2790-7.

PMID:
23246812
12.

Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.

Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM.

Cancer Res. 2007 Aug 15;67(16):7746-55.

13.

Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway.

Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li YQ, Yan TB, Sun XG, Hu P, Zhang TC.

FEBS J. 2014 Feb;281(3):927-42. doi: 10.1111/febs.12658. Epub 2014 Jan 2.

14.

Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation.

Gu G, Barone I, Gelsomino L, Giordano C, Bonofiglio D, Statti G, Menichini F, Catalano S, Andò S.

J Cell Physiol. 2012 Oct;227(10):3363-72. doi: 10.1002/jcp.24035.

PMID:
22213398
15.

Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer.

Lin Z, Yin P, Reierstad S, O'Halloran M, Coon VJ, Pearson EK, Mutlu GM, Bulun SE.

Oncogene. 2010 Feb 25;29(8):1114-22. doi: 10.1038/onc.2009.409. Epub 2009 Nov 23.

16.

Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.

Swetzig WM, Wang J, Das GM.

Oncotarget. 2016 Mar 29;7(13):16049-69. doi: 10.18632/oncotarget.7533.

17.

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC.

Cancer Res. 2010 Feb 1;70(3):1184-94. doi: 10.1158/0008-5472.CAN-09-3068. Epub 2010 Jan 19.

18.

Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.

Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard MV, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ.

J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.

PMID:
24687952
19.

A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.

Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J.

Breast Cancer Res. 2011 Jan 11;13(1):R3. doi: 10.1186/bcr2804. Erratum in: Breast Cancer Res. 2012;14(2):302.

Supplemental Content

Support Center